References
- World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19: 11 March 2020 [Internet]. Geneva: World Health Organization; 2020 [cited 2023 May 15]. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
- Pagano L, Salmanton-Garcia J, Marchesi F, et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol 2021;14:168.
- Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood 2020;136:2881-92. https://doi.org/10.1182/blood.2020008824
- Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020;383:2603-15. https://doi.org/10.1056/NEJMoa2034577
- Pharmaceutical and Medical Devices Agency. Special approval for emergency on first COVID-19 vaccine in Japan [Internet]. Tokyo: Pharmaceutical and Medical Devices Agency; 2021 [cited 2022 Dec 5]. https://www.pmda.go.jp/english/about-pmda/0003.pdf
- Painter MM, Mathew D, Goel RR, et al. Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. Immunity 2021;54:2133-42. https://doi.org/10.1016/j.immuni.2021.08.001
- Herzog Tzarfati K, Gutwein O, Apel A, et al. BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies. Am J Hematol 2021;96:1195-203. https://doi.org/10.1002/ajh.26284
- Harvey RA, Rassen JA, Kabelac CA, et al. Association of SARS-CoV-2 seropositive antibody test with risk of future infection. JAMA Intern Med 2021;181:672-9. https://doi.org/10.1001/jamainternmed.2021.0366
- Okamoto A, Fujigaki H, Iriyama C, et al. CD19-positive lymphocyte count is critical for acquisition of anti-SARS-CoV-2 IgG after vaccination in B-cell lymphoma. Blood Adv 2022;6:3230-3. https://doi.org/10.1182/bloodadvances.2021006302
- Bitoun S, Henry J, Vauloup-Fellous C, et al. Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls. J Hematol Oncol 2021;14:166.
- Petzer V, Steiner N, Angelova-Unterberger O, et al. Serologic responses to COVID-19 vaccines in hematological patients are predominantly impaired in lymphoid but not in myeloid malignancies. Hemasphere 2022;6:e686.
- Kayukawa S, Nanya K, Morita M, Ina K, Ota Y, Hasegawa S. Spike antibody titers evaluation after a 2-dose regimen of BNT162b2 vaccination in healthcare workers previously infected with SARS-CoV-2. Microbiol Spectr 2021;9:e0103621.
- Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 2013;48:452-8. https://doi.org/10.1038/bmt.2012.244
- Parthymou A, Habeos EE, Habeos GI, et al. Factors associated with anti-SARS-CoV-2 antibody titres 3 months post-vaccination with the second dose of BNT162b2 vaccine: a longitudinal observational cohort study in western Greece. BMJ Open 2022;12:e057084.
- Takahashi W, Mizuno T, Hara K, et al. Association of systemic adverse reactions and serum SARS-CoV-2 spike protein antibody levels after administration of BNT162b2 mRNA COVID-19 vaccine. Intern Med 2022;61:3205-10. https://doi.org/10.2169/internalmedicine.9699-22
- Maneikis K, Sablauskas K, Ringeleviciute U, et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol 2021;8:e583-92. https://doi.org/10.1016/S2352-3026(21)00169-1
- Gur I, Giladi A, Isenberg YN, Neuberger A, Stern A. COVID-19 in patients with hematologic malignancies: clinical manifestations, persistence, and immune response. Acta Haematol 2022;145:297-309. https://doi.org/10.1159/000523872
- Katagiri S, Akahane D, Otsuki S, et al. Tyrosine kinase inhibitors do not promote a decrease in SARS-CoV-2 anti-spike IgG after BNT162b2 vaccination in chronic myeloid leukemia: a prospective observational study. Vaccines (Basel) 2022;10:1404.
- Haggenburg S, Hofsink Q, Lissenberg-Witte BI, et al. Antibody response in immunocompromised patients with hematologic cancers who received a 3-dose mRNA-1273 vaccination schedule for COVID-19. JAMA Oncol 2022;8:1477-83. https://doi.org/10.1001/jamaoncol.2022.3227
- Anolik JH, Friedberg JW, Zheng B, et al. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol 2007;122:139-45. https://doi.org/10.1016/j.clim.2006.08.009
- Susol O, Hajkova B, Zelena H, Hajek R. Third dose of COVID-19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres. Br J Haematol 2022;197:302-5. https://doi.org/10.1111/bjh.18073